IFNAR1 and infection: To determine whether or not the observed antiviral effect of PML at these times of infection was a secondary response to IFN synthesis, we tested the capacity of PMLIV to inhibit VSV in cells treated with an anti-IFNAR1 mAb targeting the extracellular domain of the IFNAR1 chain of the human IFN-α/β receptor.